Literature DB >> 22822001

Dasatinib may overcome the negative prognostic impact of KIR2DS1 in newly diagnosed patients with chronic myeloid leukemia.

Sara Ali, Ruhena Sergeant, Stephen G O'Brien, Letizia Foroni, Corinne Hedgley, Gareth Gerrard, Dragana Milojkovic, Kate Stringaris, Ahmad Khoder, Abdullah Alsuliman, Maria Gilleece, Ian H Gabriel, Nichola Cooper, John M Goldman, Jane F Apperley, Richard E Clark, David Marin, Katayoun Rezvani.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22822001      PMCID： PMC6143148          DOI： 10.1182/blood-2012-04-421016

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  10 in total

1.  Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.

Authors:  David Marin; Amr R Ibrahim; Claire Lucas; Gareth Gerrard; Lihui Wang; Richard M Szydlo; Richard E Clark; Jane F Apperley; Dragana Milojkovic; Marco Bua; Jiri Pavlu; Christos Paliompeis; Alistair Reid; Katayoun Rezvani; John M Goldman; Letizia Foroni
Journal:  J Clin Oncol       Date:  2011-11-07       Impact factor: 44.544

2.  Dasatinib suppresses in vitro natural killer cell cytotoxicity.

Authors:  Stephen J Blake; A Bruce Lyons; Cara K Fraser; John D Hayball; Timothy P Hughes
Journal:  Blood       Date:  2008-04-15       Impact factor: 22.113

3.  The antileukemia effect of HLA-matched NK and NK-T cells in chronic myelogenous leukemia involves NKG2D-target-cell interactions.

Authors:  Giuseppe Sconocchia; Michelle Lau; Maurizio Provenzano; Katayoun Rezvani; Wachanan Wongsena; Hiroshi Fujiwara; Nancy Hensel; Jos Melenhorst; Jonming Li; Soldano Ferrone; A John Barrett
Journal:  Blood       Date:  2005-07-26       Impact factor: 22.113

4.  Factors associated with early molecular remission after T cell-depleted allogeneic stem cell transplantation for chronic myelogenous leukemia.

Authors:  Bipin N Savani; Katayoun Rezvani; Stephan Mielke; Aldemar Montero; Roger Kurlander; Charles S Carter; Susan Leitman; Elizabeth J Read; Richard Childs; A John Barrett
Journal:  Blood       Date:  2005-08-30       Impact factor: 22.113

5.  Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial.

Authors:  François-Xavier Mahon; Delphine Réa; Joëlle Guilhot; François Guilhot; Françoise Huguet; Franck Nicolini; Laurence Legros; Aude Charbonnier; Agnès Guerci; Bruno Varet; Gabriel Etienne; Josy Reiffers; Philippe Rousselot
Journal:  Lancet Oncol       Date:  2010-10-19       Impact factor: 41.316

6.  Interaction between KIR3DS1 and HLA-Bw4 predicts for progression-free survival after autologous stem cell transplantation in patients with multiple myeloma.

Authors:  Ian H Gabriel; Ruhena Sergeant; Richard Szydlo; Jane F Apperley; Hugues DeLavallade; Abdullah Alsuliman; Ahmad Khoder; David Marin; Edward Kanfer; Nichola Cooper; John Davis; Donald MacDonald; Marco Bua; Letizia Foroni; Chrissy Giles; Dragana Milojkovic; Amin Rahemtulla; Katayoun Rezvani
Journal:  Blood       Date:  2010-06-18       Impact factor: 22.113

7.  KIR2DS1 genotype predicts for complete cytogenetic response and survival in newly diagnosed chronic myeloid leukemia patients treated with imatinib.

Authors:  D Marin; I H Gabriel; S Ahmad; L Foroni; H de Lavallade; R Clark; S O'Brien; R Sergeant; C Hedgley; D Milojkovic; J S Khorashad; M Bua; A Alsuliman; A Khoder; K Stringaris; N Cooper; J Davis; J M Goldman; J F Apperley; K Rezvani
Journal:  Leukemia       Date:  2011-08-16       Impact factor: 11.528

8.  Mono/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy.

Authors:  Anna Kreutzman; Vesa Juvonen; Veli Kairisto; Marja Ekblom; Leif Stenke; Ruth Seggewiss; Kimmo Porkka; Satu Mustjoki
Journal:  Blood       Date:  2010-04-22       Impact factor: 22.113

Review 9.  Human natural killer cells.

Authors:  Michael A Caligiuri
Journal:  Blood       Date:  2008-08-01       Impact factor: 22.113

10.  Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets.

Authors:  Uwe Rix; Oliver Hantschel; Gerhard Dürnberger; Lily L Remsing Rix; Melanie Planyavsky; Nora V Fernbach; Ines Kaupe; Keiryn L Bennett; Peter Valent; Jacques Colinge; Thomas Köcher; Giulio Superti-Furga
Journal:  Blood       Date:  2007-08-24       Impact factor: 22.113
  10 in total
  3 in total

Review 1.  Opportunities and limitations of natural killer cells as adoptive therapy for malignant disease.

Authors:  James O J Davies; Kate Stringaris; A John Barrett; Katayoun Rezvani
Journal:  Cytotherapy       Date:  2014-05-20       Impact factor: 5.414

Review 2.  Immunology and immunotherapy of chronic myeloid leukemia.

Authors:  Mette Ilander; Can Hekim; Satu Mustjoki
Journal:  Curr Hematol Malig Rep       Date:  2014-03       Impact factor: 3.952

3.  Novel immune modulators used in hematology: impact on NK cells.

Authors:  Stephanie Krieg; Evelyn Ullrich
Journal:  Front Immunol       Date:  2013-01-03       Impact factor: 7.561
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.